Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ensysce Biosciences ( (ENSC) ) just unveiled an announcement.
On April 1, 2026, Ensysce Biosciences Inc. announced that board member Curtis Rosebraugh resigned from the company’s Board of Directors, effective the same day. Rosebraugh also stepped down from his role on the Nominating and Corporate Governance Committee, a move that may prompt adjustments in the company’s governance structure and board committee composition as it refills this oversight position.
The most recent analyst rating on (ENSC) stock is a Hold with a $0.52 price target. To see the full list of analyst forecasts on Ensysce Biosciences stock, see the ENSC Stock Forecast page.
Spark’s Take on ENSC Stock
According to Spark, TipRanks’ AI Analyst, ENSC is a Neutral.
The score is primarily held down by weak financial performance, marked by revenue collapse, large and worsening losses, and sustained cash burn. Technicals also reflect a broader downtrend with only neutral momentum. Valuation metrics are not favorable due to negative earnings and no dividend yield, while the recent corporate action approvals provide some structural support but do not offset the financial risk.
To see Spark’s full report on ENSC stock, click here.
More about Ensysce Biosciences
Ensysce Biosciences Inc. operates in the biopharmaceutical sector, focusing on the development of prescription drug products. The company is oriented around research-driven innovation, with its governance and board structure supporting its strategic and regulatory responsibilities in the healthcare and life sciences market.
Average Trading Volume: 6,008,169
Technical Sentiment Signal: Sell
Current Market Cap: $5.66M
For an in-depth examination of ENSC stock, go to TipRanks’ Overview page.